Výsledky vyhledávání

< Back Martin Kovalčík Communications For almost 13 years, Martin worked as a media coordinator for the respected Czech non-profit organization, People in Need, where he was responsible for the media service for a team of 300 people. Also, he has experience working in several editorial offices. He left his most significant mark at the Metro newspaper, where he worked for over 5 years, the last two as the deputy editor-in-chief.

< Back Roberto Fernandez Project Manager Roberto Fernandez is a Project manager at i&i Prague. He holds a BSc in Chemistry from the University of Costa Rica and a MSc in Biochemistry and Biotechnology from Autonomous University of Barcelona. Prior to joining our company Roberto completed his Ph.D. in Macromolecular Chemistry at Charles University, Czech Republic. His multicultural and multidisciplinary background built his interest for applied science, technology transfer and the positive changes this brings to society. In his last year of Ph.D., he participated in the management internship program started by i&i Prague, which provided hands-on experience working at a start-up in the portfolio of i&i Prague. Parallel to his work in i&i Prague, Roberto works as a project manager in the MedTech start-up LAM-X a.s. Due to his experience, Roberto prefers to focus on projects in the field of medical devices and drug delivery.

< Back Simona Šandová Office Manager During her career, Simona has worked as an Office Manager and a Junior Property Manager. She was responsible for training and conference organization, communication with clients and suppliers as well as administrative assistance for the project and property department. She has considerable experience in administration and office management.

< Back Jiří Růžička Project Manager Jiri Ruzicka is a Project manager at i&i Prague. He is responsible for the analysis of projects, mainly from the scientific and technological aspect. Before joining our company Jiri worked as a Research Associate at the Institute of Experimental Medicine (IEM, part of the Czech Academy of Sciences), as well as within the international research center of IEM, University of Cambridge, and University of Leeds, called Neurorecon. He holds BSc. and MSc. Degrees from the Faculty of Science, Charles University. He has done his Ph.D. at IEM, AS CR, and the 2nd Faculty of Medicine of Charles University. During his postdoc as a member of the Neurorecon team he spent several months at Imperial College London and had close collaboration with the University of Cambridge, including several short research stays. He has 14+ years’ experience in the fields of neuroscience and regenerative medicine with a broad focus on brain/spinal cord injuries, neurodegenerative diseases, and aging. He has been dealing with enzymatic, gene, or cell therapies, biomaterial applications, and genetic models of neurodegenerative disorders.

< Back Jiří Moos CEO, Board of Directors Jiří Moos is our Executive Director, having joined i&i Prague from DiaSorin where he was the Marketing Manager. He is also a member of the TACR GAMA Commercialization Board at the Institute of Molecular Genetics in Prague, and an external member of the Supervisory Board at the Institute of Biotechnology AS CR. Between 2008 and 2016, he acted as a Senior Sales Manager for Sigma-Aldrich (since 2015 a part of Merck KgaA), Czech Republic and Slovakia, and as a Coordinator of regional Sigma-Aldrich Applied Business Unit activities, also covering Hungary and Poland. For six years, he worked for Immunotech a.s., a Beckman-Coulter company located in Prague, first as a Product Manager in the Clinical Chemistry team and later as the Life Science Product Specialist team leader. Jiří also has extensive experience as a Scientific Researcher at the Centre of Assisted Reproduction, General Teaching Hospital in Prague, and as a Research Fellow at the Institute of Molecular Genetics, AS CR in Prague. Jiří Moos completed his Master´s degree in Biology and Chemistry at Charles University in Prague. He received a Ph.D. (CSc.) in Biology from the Institute of Molecular Genetics, AS CR in Prague, followed by almost 3 years of postdoctoral fellowship in the field of Biology of Reproduction at the University of Pennsylvania in Philadelphia. Jiří has also completed the Miller Heiman course of Business and Strategic Selling. If you are interested in cooperation, Jiří will probably be the person you will be meeting quite often. Maybe you are already on his radar because he is the one actively searching for new technologies and early-stage opportunities. He has been in the world of science for almost three decades and has made an extensive network of contacts both in Academia and Industry.

< Back Milan Prášil Chairman, Board of directors Milan has a thorough knowledge of a business as well as an academic environment. Functioning for eight years as a chancellor of the oldest and one of the largest universities in Central Europe, Charles University in Prague, Milan’s special assignment was a technological transfer and commercialization of academic research results. Milan is well acquainted with the entrepreneurial environment since he founded and managed a consulting company focused mainly on the assessment and improvement of clinical healthcare efficiency and the assessment and professional development of managers. Before he entered the world of entrepreneurship, Milan had spent a great deal of his early professional career developing expertise in the pharma industry. He initially worked for the Czech branches of research-oriented pharma producers (Novo Nordisk, Bayer) in various positions in sales and marketing. He later gained international senior management experience working at a multinational biotech company (Genzyme Therapeutics), where he was responsible for the process of company expansion to the regions of Central and Eastern Europe. Milan Prasil graduated from the 1st medical faculty of Charles University in Prague (1995) and got his MBA from the Rochester Institute of Technology and the U.S. Business School in Prague (1996).

< Back Iva Machová Project Manager Iva Machová is a Project manager at i&i Prague. She is responsible for the analysis of project technology. Before joining our company, Iva worked as a postdoc researcher at the Biomedical Center of the Faculty of Medicine in Pilsen. She holds BSc and MSc degrees from UCT Prague, Czech Republic, and she did her Ph.D. at the Institute of organic chemistry and biochemistry, AS CR. Iva spent several months on a postdoctoral fellowship at Ludwig-Maximilians-Universität München. Due to her scientific experience in biochemistry, she is focused on projects in the field of drug discovery and cell therapy.

< Back David Stíbal Board of Directors, Vice Director David Stíbal is the Vice Director at i&i Prague. He holds BSc and MSc degrees from UCT Prague, Czech Republic, and a Ph.D. from the University of Neuchâtel in Switzerland. After his doctorate studies, David worked as a PostDoc at the Massachusetts Institute of Technology. Prior to joining our company, David worked in Lach-Ner s.r.o. as a research scientist, developing modular catalytic systems. His international scientific experience has allowed him to develop a detail-oriented approach to projects from various fields, spanning organic and inorganic chemistry, pharmaceutical sciences, bioinorganic chemistry, and biochemistry. At i&i Prague, David has been focusing on biotechnology evaluations, intellectual property rights, and start-up formation. He will therefore be happy to help assess the scientific background of your project, offer advice during the start-up set-up and early management, and assist in the long-term project development all the way to the successful commercialization.

< Back Mikuláš Vargic External Lawyer Mikuláš studied law at Masaryk University Brno and International and European Law at the University of Antwerp. He is an independent attorney with a specialization in technology transfer. Mikuláš joined our team in 2016 and has almost ten years of experience. He previously worked in a major Czech law firm in Brno and at the South Moravian Innovation Center (JIC). He also works for other clients from both the public sector (universities and research institutions) and the private sector (investors, start-up, and spin-off companies). Mikuláš helps i&i Prague with all legal matters and is involved in negotiating transaction documentation with our partners. His knowledge of business, technical and legal matters will help you to tailor the legal framework for your specific needs.

We focus on unique ideas that have the potential to succeed on a global scale. We are dedicated to innovations in Drug Discovery, Diagnostics, MedTech and other Life Science fields that originate from academic institutions. Our portfolio We help invention grow! We help turn groundbreaking scientific discoveries into successful startups and spin-offs. By connecting innovation with capital and expertise, we create growth opportunities. Our objective is to identify new inventions in Drug Discovery, Diagnostics, MedTech and other Life Science fields. This is an overview of our current portfolio companies: ADALID SCIENCES Focus: Novel lipid nanoparticles for effective drug delivery Field: Drug discovery Country: Czech Republic Read More CASINVENT PHARMA Focus: Casein Kinase 1 inhibitors for cancer treatment Field: Drug discovery Country: Czech Republic Read More DEEP MEDCHEM Focus: AI-based tools accelerating drug discovery Field: Others Country: Czech Republic Read More DRACEN PHARMACEUTICALS Focus: Tumor-Directed Glutamine Antagonist Field: Drug discovery Country: Czech Republic/United States of America Read More LAM-X Focus: Light-activated nanomaterials fighting infections Field: MedTech Country: Czech Republic Read More PEP-THERAPY Focus: Innovative peptides for oncology Field: Drug discovery Country: France Read More PERIOTRAP Focus: Curative treatment of periodontitis Field: Drug discovery Country: Germany Read More REECYCLIUM Focus: Separation of rare earth elements from permanent magnets Field: Others Country: Czech Republic Read More SAMPLING HUMAN Focus: Yeast cell based biocomputing Field: Diagnostics Country: Czech Republic/United States of America Read More SOPHOMER Focus: Syntetic polymer for immunoassays Field: Diagnostics Country: Czech Republic Read More SULFOTOOLS Focus: Green peptide synthesis technology Field: Others Country: Germany Read More Our exits Our role is to help launch new startups or spin-offs. The moment our role ends, the exit follows. Here is an overview of our exits: DIANA BIOTECHNOLOGIES Focus: Pharmaceuticals and highly sensitive diagnostic methods Field: Diagnostics Country: Czech Republic Read More ELPHOGENE Focus: Liquid biopsy technology for cancer diagnostics Field: Diagnostics Country: Czech Republic Read More RIOCATH Focus: New technology used in the production of catheters Field: MechTech Country: Czech Republic Read More

Green chemistry start-up Sulfotools closes seed round with i&i Prague. Darmstadt (Germany) 21.04.2021 – Peptides, small proteins with a broad range of biological properties, are used as active ingredients in many different products, e.g. as therapeutics (cancer treatment), in cosmetics (anti-aging products) or nutrition products. However, only few people are aware that the chemical production of such compounds is associated with immense consumption of toxic solvents and CO2 emission. Sulfotools GmbH, as spin-off of Technical University of Darmstadt, has developed a sustainable chemical peptide production method using water instead of toxic solvents, the Clean Peptide Technology (CPT). Together with the Czech biotech incubator & investor i&i Prague, Sulfotools will commercialize its technology to make peptide production more sustainable and eco-friendlier. For economic reasons, the majority of marketed peptides are produced chemically via the socalled solid-phase peptide synthesis (SPPS, state of the art). Each year the peptide industry consumes tens of thousands tons of environmentally harmful, hazardous and expensive organic solvents for the manufacturing. Additionally, the application of such solvents is associated with significant risks for humans and the environment (immense CO2 emission). N,N-dimethylformamide (DMF), the most common solvent used for peptide synthesis is toxic, teratogen and classified as Substance of Very High Concern (SVHC) by the European Chemicals Directive REACh. Especially, in cosmetic peptides residues of these toxic solvents are problematic and therefore, the purification of such peptides is very cost intensive. Sulfotools Clean Peptide Technology (CPT) combines the advantages of chemical synthesis with the mild and sustainable conditions of recombinant production. It is based on novel watersoluble building blocks, the use of which allows for the complete substitution of toxic organic solvents with water during the manufacturing process. Additionally, CPT includes an efficient purification system, a simple wastewater treatment option and due to intrinsic fluorescent properties, for the first time a real-time monitoring of the reaction progress, altogether leading to cost savings of up to 50% and at the same time to an eco-friendly production. Moreover, solvent-free end products can be produced which is an immense advantage for the application in the field of cosmetics and food supplements. Especially cosmetic and nutrition companies using CPT can advertise the benefits of a sustainable production directly to their endcustomers. The Sulfotools GmbH was founded in March 2016 by an interdisciplinary team from Darmstadt, Germany, which is driven by a clear vision: The greening of chemical peptide synthesis. The idea was born during the PhD research of Sascha Knauer at the Technical University of Darmstadt and filed in as patent application. Within the Exist I and II program of the German Federal Ministry of Economics and Energy (BMWi) the Clean Peptide Technology was developed to market-readiness. This included the demonstration of the applicability of the CPT by the successful peptide syntheses used in cosmetics or pharmaceuticals as well as in feasibility studies for renowned industrial customers. Moreover, the manufacturing processes for the water-soluble building blocks were optimized and are ready for up-scale. Together with i&i Prague Sulfotools will scale-up of the manufacturing of the water-soluble building blocks and start the commercialization of the technology. (www.sulfotools.com )

Licensing agreement for a novel SARS Cov-2 virus neutralization antibody test was signed We are very happy to inform you that i&i Prague has participated on a development of novel in vitro diagnostics test measuring virus neutralization antibodies against SARS Cov-2 in human blood. The project was successfully completed and the Institute of Organic Chemistry and Biochemistry (IOCB) and the Institute of Biotechnology (IBT) have signed an exclusive license agreement with the company Immunotech, the Prague based subsidiary of Beckman Coulter. Read more information on IOCB webpage. 12 mouse monoclonal antibody clones against different domains of SARS Cov-2 Spike protein were generated in this project and are available for research or other use. For more information about the new test and the available antibody clones, contact: Dr. Jiří Moos moos@iniprague.com